Bristol-Myers Squibb Deal History & Licensing Activity
Bristol-Myers Squibb is a large pharma headquartered in US. Over the past three years, Bristol-Myers Squibb has been involved in 19 licensing and acquisition transactions, with a primary focus on Other (5 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
10
Active Trials
50
Top Modality
Other
Focus Area
Oncology
Bristol-Myers Squibb Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bristol-Myers Squibb in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Bristol Myers Squibb | Oligonucleotides | Discovery | collaboration | Aug 13, 2026 |
| CeeNU (Lomustine) | Septa Pharmaceuticals Inc. | Small Molecules | Approved | acquisition | Jun 29, 2026 |
| Portfolio of 13 early-stage programs (oncology, hematology, immunology) | Bristol Myers Squibb | Other | Discovery | collaboration | May 12, 2026 |
| SYNtecan linker-payload platform | Lonza | ADC | Unknown | license | May 7, 2026 |
| Undisclosed | Bristol Myers Squibb | Bispecific Antibodies | Discovery | collaboration | Apr 9, 2026 |
| Undisclosed | Bristol Myers Squibb | Bispecific Antibodies | Preclinical | collaboration | Jan 22, 2026 |
| Undisclosed | Bristol Myers Squibb | Antibodies | Discovery | collaboration | Dec 16, 2025 |
| Undisclosed | Bristol Myers Squibb | Small Molecules | Discovery | collaboration | Nov 12, 2025 |
| Undisclosed | Bristol Myers Squibb | Other | Discovery | collaboration | Oct 27, 2025 |
Bristol-Myers Squibb Pipeline Focus
Therapeutic areas and modalities where Bristol-Myers Squibb is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Bristol-Myers Squibb Strategic Signals
Key indicators of Bristol-Myers Squibb's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Bristol-Myers Squibb Clinical Pipeline
Bristol-Myers Squibb has 50 active clinical trials across 7 development phases.
3
Unknown
1
Phase 4
6
Phase 1
4
Phase 1/2
10
Phase 2
2
Phase 2/3
24
Phase 3
See How Your Asset Matches Bristol-Myers Squibb's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Bristol-Myers Squibb Licensing & Deal Activity
Bristol-Myers Squibb is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 19 deals over the past three years, Bristol-Myers Squibb ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bristol-Myers Squibb include Oncology (14 deals and trials), Solid Tumors (12 deals and trials), Autoimmune (7 deals and trials), and Neurology (6 deals and trials). In terms of modality, Bristol-Myers Squibb has shown particular interest in other, bispecific antibodies, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bristol-Myers Squibb and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Bristol-Myers Squibb's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.